FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

OMB APP	OMB APPROVAL									
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					-				iiivesiiieii											
Name and Address of Reporting Person* Underdown Brian J.					2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VTGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
														X	Directo	r		10% Ov	vner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)									Officer below)	(give title		Other (s below)	specify		
C/O VISTAGEN THERAPEUTICS, INC.				12/	12/30/2020															
343 ALLERTON AVENUE									- f Out of the - 1 I	F111	(11									
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
SOUTH	SAN ,	CA.	94080											X		,		orting Perso		
FRANCI	ISCO	ΔA	94080												Form filed by More than One Reporting Person					
(City)	(:	State)	(Zip)																	
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired,	Dis	osed o	f, or Be	neficia	lly C	wned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,			Code (Instr. 5)				4 and Securitie Benefici Owned F		es Form ally (D) of Following (I) (II		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code V Amount (A) or (D)				Price	1	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Dei	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)	(D)	Date Exercisab		expiration Pate	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$1.77	12/30/2020			A		75,000		(1)	1	2/30/2030	Common Stock	75,000		\$0	75,00	0	D		

Explanation of Responses:

1. Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date.

/s/ Jerrold D. Dotson, Attorney- 01/04/2021 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.